MKMin Kang

Min Kang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Min Kang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Feng He

    Department of Biochemistry and Immunology, Capital Institute of Pediatrics, No. 2 Yabao Road, Chao Yang District, Beijing, 100020, China

    1 shared publication
  • Hailan Yao

    Department of Biochemistry and Immunology, Capital Center for Children’s Health, Capital Medical University, Capital Institute of Pediatrics, China

    1 shared publication
  • Jianxin Wu

    Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, China

    1 shared publication
  • Miao Feng

    Department of Biochemistry and Immunology, Capital Institute of Pediatrics, Beijing, 100020, China

    1 shared publication
  • Zhewei Liu

    Department of Biochemistry and Immunology, Capital Institute of Pediatrics, No. 2 Yabao Road, Chao Yang District, Beijing, 100020, China

    1 shared publication
  • Zonghui Xiao

    Department of Biochemistry and Immunology, Capital Institute of Pediatrics, No. 2 Yabao Road, Chao Yang District, Beijing, 100020, China

    1 shared publication

Latest Publications

  • Open Access

    Plasma interleukin-37 is increased and inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells in systemic juvenile idiopathic arthritis patients

    by Miao Feng, Min Kang, Feng He, Zonghui Xiao, Zhewei Liu, Hailan Yao, Jianxin Wu

    Interleukin (IL)-37 has emerged as a novel anti-inflammatory cytokine that play an immunosuppressive role in regulating inflammatory response. This study aimed to measure IL-37 levels in the plasma and peripheral blood mononuclear cells (PBMCs) of patients with systemic juvenile idiopathic arthritis (sJIA), and to establish the correlation between IL-37 levels and disease activity, laboratory parameters and inflammatory cytokines. The mRNA levels of IL-37 in PBMCs and plasma IL-37 concentrations in 46 sJIA patients and 30 age- and sex-matched healthy controls were measured by real-time polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA), respectively. The correlations between plasma IL-37 levels and disease activity, laboratory parameters and inflammatory cytokines in sJIA were analyzed by Spearman correlation test. PBMCs from the sJIA patients were stimulated with recombinant human IL-37 (rhIL-37) protein, expressions of IL-1β, IL-6, TNF-α and IL-17 were detected by RT-PCR and ELISA. Plasma levels of IL-37 and relative IL-37 mRNA expression were significantly elevated in sJIA patients, especially in active sJIA patients, when compared with the healthy controls (P < 0.001). Furthermore, patients with active disease showed higher IL-37 mRNAs and plasma protein levels than those with inactive disease as well as healthy controls. Plasma IL-37 levels were correlated with disease activity and inflammatory cytokines (IL-6, TNF-α, IL-17 and GM-CSF) in sJIA patients. The productions of inflammatory cytokines such as IL-6, TNF-α, IL-17 in PBMCs from sJIA patients were obviously decreased after recombinant IL-37 stimulation, whereas the production of IL-1β was not changed. Our results demonstrate that levels of IL-37 were higher in sJIA patients, which were correlated with disease activity and sJIA related inflammatory cytokines. In addition, rhIL-37 down-regulates the expressions of inflammatory cytokines form PBMCs in sJIA patients, suggesting that IL-37 may have the potential role as a natural inhibitor for the pathogenesis and therapy of sJIA.